Zevra Therapeutics Long Term Debt

The latest long-term debt for KMPH is $740K as of March 2026. That compares with $61M in the prior-year period — down 98.8% year over year. Investors often review this figure alongside Zevra Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, KMPH's long-term debt moved from $61M to $740K — a 98.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zevra Therapeutics's operating scale or balance-sheet position.

A long-term debt figure of $740K for KMPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting KMPH's long-term debt ($740K), review year-over-year change from $61M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Zevra Therapeutics's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.